- Previous Close
88.15 - Open
87.43 - Bid 86.98 x --
- Ask 87.03 x --
- Day's Range
86.85 - 88.12 - 52 Week Range
83.65 - 102.72 - Volume
607,351 - Avg. Volume
507,555 - Market Cap (intraday)
175.122B - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
17.03 - EPS (TTM)
5.11 - Earnings Date Jan 31, 2025
- Forward Dividend & Yield 3.30 (3.74%)
- Ex-Dividend Date Mar 7, 2024
- 1y Target Est
--
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
www.novartis.com76,057
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NOVNZ.XC
View MorePerformance Overview: NOVNZ.XC
Trailing total returns as of 12/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NOVNZ.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NOVNZ.XC
View MoreValuation Measures
Market Cap
176.02B
Enterprise Value
192.21B
Trailing P/E
17.24
Forward P/E
12.05
PEG Ratio (5yr expected)
2.94
Price/Sales (ttm)
4.06
Price/Book (mrq)
4.56
Enterprise Value/Revenue
4.31
Enterprise Value/EBITDA
10.93
Financial Highlights
Profitability and Income Statement
Profit Margin
35.25%
Return on Assets (ttm)
10.59%
Return on Equity (ttm)
28.79%
Revenue (ttm)
49.94B
Net Income Avi to Common (ttm)
11.76B
Diluted EPS (ttm)
5.11
Balance Sheet and Cash Flow
Total Cash (mrq)
13.85B
Total Debt/Equity (mrq)
74.03%
Levered Free Cash Flow (ttm)
5.68B